Sapient Capital LLC Reduces Position in Elanco Animal Health Incorporated (NYSE:ELAN)

Sapient Capital LLC trimmed its stake in Elanco Animal Health Incorporated (NYSE:ELAN) by 2.3% in the first quarter, HoldingsChannel.com reports. The fund owned 136,077 shares of the company’s stock after selling 3,269 shares during the quarter. Sapient Capital LLC’s holdings in Elanco Animal Health were worth $1,429,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in ELAN. FMR LLC lifted its stake in shares of Elanco Animal Health by 1,153.6% during the fourth quarter. FMR LLC now owns 40,232,327 shares of the company’s stock valued at $487,213,000 after buying an additional 37,022,891 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of Elanco Animal Health by 6.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 17,900,987 shares of the company’s stock worth $216,774,000 after purchasing an additional 1,074,274 shares during the period. Shapiro Capital Management LLC boosted its holdings in shares of Elanco Animal Health by 7.5% during the fourth quarter. Shapiro Capital Management LLC now owns 12,356,702 shares of the company’s stock worth $149,640,000 after purchasing an additional 862,900 shares during the last quarter. Magnetar Financial LLC grew its position in shares of Elanco Animal Health by 13.7% in the fourth quarter. Magnetar Financial LLC now owns 12,032,325 shares of the company’s stock valued at $145,711,000 after purchasing an additional 1,454,082 shares during the period. Finally, Geode Capital Management LLC grew its position in shares of Elanco Animal Health by 4.0% in the fourth quarter. Geode Capital Management LLC now owns 8,180,840 shares of the company’s stock valued at $99,102,000 after purchasing an additional 312,165 shares during the period. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Elanco Animal Health Stock Performance

Elanco Animal Health stock opened at $14.19 on Friday. The company has a market cap of $7.05 billion, a price-to-earnings ratio of 35.48, a price-to-earnings-growth ratio of 2.50 and a beta of 1.67. Elanco Animal Health Incorporated has a 12 month low of $8.02 and a 12 month high of $18.55. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. The stock’s 50-day moving average is $11.27 and its 200-day moving average is $11.44.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.37 EPS for the quarter, beating the consensus estimate of $0.31 by $0.06. The firm had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.17 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. Elanco Animal Health’s revenue for the quarter was down 1.0% compared to the same quarter last year. During the same quarter last year, the firm posted $0.34 earnings per share. Equities analysts anticipate that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on ELAN shares. UBS Group reduced their target price on Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating on the stock in a research report on Wednesday, February 26th. Barclays cut their price objective on shares of Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating on the stock in a report on Wednesday, February 26th. Stifel Nicolaus raised their target price on shares of Elanco Animal Health from $15.00 to $16.00 and gave the stock a “buy” rating in a research report on Monday, May 19th. Piper Sandler lowered their target price on shares of Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating for the company in a report on Thursday, March 6th. Finally, Morgan Stanley dropped their price target on shares of Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 26th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $15.17.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.